Table 2

Identified genes with known GO terms with a P ≤ 0.05 and ≥ 2-fold changes
Preclinical stage Clinical stage**
Term P-Value Probe Name Gene symbol Gene name FC
Compositionally biased region 4.90E-02 A_70_P049406 EIF5 Eukaryotic translation initiation factor 5, transcript variant 7 −2.65 −1.94
External side of plasma membrane 4.60E-02 A_70_P048131 GPC3 Glypican 3 −2.95 −2.56
Extracellular matrix binding 5.30E-02 A_70_P050511 NID1 Nidogen 1 −2.78 −4.15
Extracellular matrix organization 1.90E-02 A_70_P059746 CYR61 Cysteine-rich, angiogenic inducer, 61 −2.97 −3.42
A_70_P061221 P4HA1 Prolyl 4-hydroxylase, alpha polypeptide I −3.00 −2.81
Granzyme A mediated Apoptosis Pathway 6.20E-02 A_70_P054526 ANP32A Acidic (leucine-rich) nuclear phosphoprotein 32 family, member A −2.86 −2.47
A_70_P040956 GZMB Granzyme B −3.10 NSR
MHC protein binding 4.90E-02 A_70_P016891 CD3G* CD3 Gamma chain −3.20 NSR
A_70_P008201 CLEC7A C-type lectin domain family 7, member A −2.20 NSR
CUST_12481_PI375351158 TRD@ T-cell receptor delta chain −3.30 NSR
Organelle lumen 6.80E-02 A_70_P037521 FGB Fibrinogen beta chain −2.44 NSR
A_70_P020146 MRPL39 Mitochondrial ribosomal protein L39 −2.37 NSR
A_70_P036101 NOP10 NOP10 ribonucleoprotein homolog (yeast) (NOP10), mRNA −3.34 NSR
A_70_P007556 SUMF1 Sulfatase modifying factor 1 −2.11 NSR
Phosphoprotein 1.30E-03 A_70_P037146 ACOX3 Acyl-Coenzyme A oxidase 3, pristanoyl −2.23 −1.73
A_70_P021671 ARPC3 Actin related protein 2/3 complex, subunit 3, 21 kDa −2.46 NSR
A_70_P019041 ATP8B2 Similar to ATPase, class I, type 8B, member 2 −2.19 −1.78
A_70_P024516 CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1) −2.03 −1.71
A_70_P001561 FOS FBJ murine osteosarcoma viral oncogene homolog −2.86 −2.66
A_70_P008036 LAPTM4A Lysosomal protein transmembrane 4 alpha −2.58 −2.10
A_70_P018586 LAPTM4B* Lysosomal protein transmembrane 4 beta −3.65 −2.80
A_70_P049041 MAT2A Methionine adenosyl transferase II, alpha −2.24 −1.63
A_70_P006536 MGMT PREDICTED: O-6-methylguanine-DNA methyltransferase −2.89 −2.22
A_70_P030701 NES Nestin 2.02 2.55
A_70_P026261 SLC16A1 Solute carrier family 16, member 1 (monocarboxylic acid transporter 1) −2.65 −2.34
A_70_P027206 SLC30A1 Solute carrier family 30 (zinc transporter), member 1 2.45 2.27
A_70_P018386 SLC44A1 CDW92 antigen, transcript variant 2 −2.27 NSR
A_70_P059781 UBE2E1 Ubiquitin-conjugating enzyme E2E 1, transcript variant 2 −2.31 NSR
A_70_P031441 VCL Vinculin, transcript variant 2 −2.01 NSR
A_70_P022731 WDR33 WD repeat domain 33 −2.54 NSR
A_70_P033291 LOC618584 Zinc finger, CCHC domain containing 2 −2.08 −1.87
A_70_P043106 ZNF428 Zinc finger protein 428, transcript variant 2 −2.28 −2.27
Response to a biotic stimulus 4.00E-02 CUST_10550_PI375351158 BTG2 B cell translocation protein 2 −2.41 NSR
Response to fungus 4.90E-02 A_70_P050991 GNLY* Granulysin −3.97 NSR
Tight junction assembly 5.60E-02 A_70_P003466 MPP7 membrane protein, palmitoylated 7 (MAGUK p55 subfamily member 7) (MPP7), mRNA 2.93 NSR

Shown are the Blast results of the clones with significant alterations in gene expression (P ≤ 0.05 and ≥ 2-fold change). FC of significant alteration during clinical stage is given in the last column (NSR: no significant regulation). The GO was determined using on-line functional annotation of DAVID Bioinformatics Resources 2008 (NIAID/NIH, USA). Only the genes with a known GO are shown.

*Genes chosen for validation by quantitative RT-PCR.

**FC values obtained in a previous study developed by our group comparing scrapie-infected animals in a clinical stage and controls [25].

Filali et al.

Filali et al. BMC Genomics 2012 13:399   doi:10.1186/1471-2164-13-399

Open Data